Salix Pharmaceuticals (SLXP +2%) trades higher after beating bottom line Q2 estimates yesterday....

|About: Salix Pharmaceuticals, Ltd. (SLXP)|By:, SA News Editor

Salix Pharmaceuticals (SLXP +2%) trades higher after beating bottom line Q2 estimates yesterday. Net profit rose 4.6% as the drug developer saw continued strength in sales of its Xifaxan tablets. The company also raised its FY12 outlook to $2.86 per share, up from its previous view of $2.59 a share, reflecting its March placement of $690M in senior notes.